This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aravive (ARAV) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of -26.19% and 2.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Stock Moves -1.47%: What You Should Know
by Zacks Equity Research
In the latest trading session, Aravive (ARAV) closed at $14.11, marking a -1.47% move from the previous day.
Aravive (ARAV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Aravive (ARAV) closed at $13.55 in the latest trading session, marking a -0.88% move from the prior day.
Aravive (ARAV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aravive (ARAV) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.
Aravive (ARAV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.
Is ARAVIVE, INC (ARAV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARAV) Outperforming Other Medical Stocks This Year?
Aravive's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aravive.
bluebird bio (BLUE) Catches Eye: Stock Jumps 6%
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th
Aravive (ARAV) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Myovant Sciences (MYOV) Jumps: Stock Rises 8.3%
by Zacks Equity Research
Myovant Sciences (MYOV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Aravive (ARAV): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session
by Yash Killa
Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Implied Volatility Surging for Aravive (ARAV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of 51.79% and 205.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?